EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Differential Secondary Reconstitution of In Vivo -Selected Human SCID-Repopulating Cells in NOD/SCID versus NOD/SCID/γ chain null Mice

Shanbao Cai, Haiyan Wang, Barbara Bailey, Jennifer R. Hartwell, Jayne M. Silver, Beth E. Juliar, Anthony L. Sinn, Arthur R. Baluyut, Karen E. Pollok

Bone Marrow Research · 2011

DOI: 10.1155/2011/252953 ↗
AbstractBibliografische Angaben

Abstract

Humanized bone-marrow xenograft models that can monitor the long-term impact of gene-therapy strategies will help facilitate evaluation of clinical utility. The ability of the murine bone-marrow microenvironment in NOD/SCID versus NOD/SCID/ γ chain null mice to support long-term engraftment of MGMT P140K -transduced human-hematopoietic cells following alkylator-mediated in vivo selection was investigated. Mice were transplanted with MGMT P140K -transduced CD34 + cells and transduced cells selected in vivo . At 4 months after transplantation, levels of human-cell engraftment, and MGMT P140K -transduced cells in the bone marrow of NOD/SCID versus NSG mice varied slightly in vehicle- and drug-treated mice. In secondary transplants, although equal numbers of MGMT P140K -transduced human cells were transplanted, engraftment was significantly higher in NOD/SCID/ γ chain null mice compared to NOD/SCID mice at 2 months after transplantation. These data indicate that reconstitution of NOD/SCID/ γ chain null mice with human-hematopoietic cells represents a more promising model in which to test for genotoxicity and efficacy of strategies that focus on manipulation of long-term repopulating cells of human origin.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →